Recently, a sudden outbreak of novel coronavirus disease (COVID-19) was caused by a zoonotic virus known as severe acute respiratory syndrome coronavirus (SARS-CoV-2). It has caused pandemic situations around the globe affecting the lives of millions of people. So far, no drug has been approved for the treatment of SARS-CoV-2 infected patients. As of now, more than 1000 clinical trials are going on for repurposing of FDA-approved drugs and for evaluating the safety and efficiency of experimental antiviral molecules to combat COVID-19. Since the development of new drugs may require months to years to reach the market, this review focusses on the potential of existing small molecule FDA approved drugs and the molecules already in the clinical pipeline against viral infections like HIV, hepatitis B, Ebola virus, and other viruses of coronavirus family (SARS-CoV and MERS-CoV). The review also discusses the natural products and traditional medicines in clinical studies against COVID-19. Currently, 1978 studies are active, 143 completed and 4 posted results (as of June 13, 2020) on clinicaltrials.gov.

最近，新型冠状病毒病 (COVID-19) 的突然爆发是由一种被称为严重急性呼吸系统综合症冠状病毒 (SARS-CoV-2) 的人畜共患病毒引起的。它已在全球造成大流行病，影响了数百万人的生活。到目前为止，还没有任何药物被批准用于治疗 SARS-CoV-2 感染患者。截至目前，正在进行 1000 多项临床试验，以重新利用 FDA 批准的药物，并评估实验性抗病毒分子对抗 COVID-19 的安全性和有效性。由于新药的开发可能需要数月至数年才能上市，因此本次审查重点关注现有小分子药物的潜力以及已进入临床管道的分子，以对抗 HIV、乙型肝炎、埃博拉病毒、和冠状病毒家族的其他病毒（SARS-CoV 和 MERS-CoV）。该评论还讨论了针对 COVID-19 的临床研究中的天然产物和传统药物。目前，clinicaltrials.gov 上有 1978 项研究处于活跃状态，143 项已完成，4 项结果已公布（截至 2020 年 6 月 13 日）。